[{"id":"a3a220de-7a96-43ff-89c7-a0794035b138","acronym":"","url":"https://clinicaltrials.gov/study/NCT04570839","created_at":"2021-02-23T17:55:29.030Z","updated_at":"2025-02-25T14:29:35.860Z","phase":"Phase 1/2","brief_title":"COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.","source_id_and_acronym":"NCT04570839","lead_sponsor":"Compugen Ltd","biomarkers":" TNFRSF9","pipe":"","alterations":" ","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-07-18"},{"id":"66601efc-29f2-40ed-998d-6081f1706758","acronym":"","url":"https://clinicaltrials.gov/study/NCT02913313","created_at":"2021-07-05T16:57:38.947Z","updated_at":"2024-07-02T16:35:11.765Z","phase":"Phase 1/2","brief_title":"A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors","source_id_and_acronym":"NCT02913313","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 11/30/2016","start_date":" 11/30/2016","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2024-04-03"}]